Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2023-08-21 00:00:00 ET · period of report 2023-08-17 · accession 0001933414-23-000065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-21 | 2023-08-17 | MLYS | Congleton Jon | CEO, Dir | P - Purchase | $12.10 | +2,250 | 1.04M | +0.2% | +$27.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-17 | P | A | 2,250 | $12.10 | 1,042,568 | D | — | — | (F1) The price reported is the weighted-average purchase price, purchased in multiple transactions at prices ranging from $12.02 to $12.1473. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. |